Asha D, Jeganath S, Bupesh G, Sahoo UK, Bhaskar M, Pandian K. Controlled drug release for inflammatory bowel disease (IBD).
Bioinformation 2020;
16:513-524. [PMID:
32994676 PMCID:
PMC7505240 DOI:
10.6026/97320630016513]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/01/2020] [Revised: 05/31/2020] [Accepted: 06/04/2020] [Indexed: 11/23/2022] Open
Abstract
Controlled drug release in formulation is an important area of research. Formulations using crospovidone as super-disintegrants to achieve immediate release once it reaches the ileo- cecal region is relevant. The Eudragit L30D pH dependent polymer that allows drug release after a lag time of 4-5 hrs to achieve desired drug release from the drug delivery system is critical. Hence, pre-formulation to study drug-polymer interaction is essential. The linear correlation between the predicted and actual values for all the batches of optimization is shown with high correlation coefficient (r-value). Therefore, the designed formulation is promising for ileo-cecal targeted pulsatile drug delivery system in the management of Crohn's disease.
Collapse